Market Overview:
The Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market provides various treatment options for chemotherapy-induced nausea and vomiting (CINV), a common side effect of cancer treatment. Without preventive treatment, approximately 70-80% of cancer patients receiving highly emetogenic chemotherapy experience acute vomiting after treatment within 24 hours. With the adoption of antiemetic therapies, the risk of CINV has been significantly reduced over the past few decades.
The Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market is estimated to be valued at US$ 3,071.1 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market is the emergence of targeted triple combination therapies. These combination therapies involving 5-HT3 receptor antagonists, NK1 receptor antagonists, and dexamethasone have demonstrated higher effectiveness in preventing both acute and delayed CINV compared to single or double drug regimens. For example, the triple combination of palonosetron (5-HT3), netupitant (NK1), and dexamethasone has shown complete response rates of over 90% in multiple clinical studies. The growing adoption of targeted triple therapies is expected to drive the market growth over the forecast period.
Porter’s Analysis:
Threat of new entrants: The cancer chemotherapy associated nausea and vomiting therapeutics market poses a low threat of new entrants due to high R&D and capital requirements. Established players dominate the market with strong brand visibility.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative treatment options. However, established brands have strong brand loyalty.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to the availability of substitute raw materials and differentiated products.
Threat of new substitutes: Threat of substitutes is moderate as alternative treatment options are available. However, product patenting provides protection against substitutes.
Competitive rivalry: The market experiences high competitive rivalry due to established brands competing on product differentiation and pricing.
SWOT Analysis:
Strengths: The cancer chemotherapy associated nausea and vomiting therapeutics market possesses strong R&D capabilities and a wide product portfolio catering to different treatment needs. Established brands enjoy strong brand recognition and loyalty.
Weaknesses: High capital requirements and stringent regulatory approvals pose significant challenges for new entrants. Dependence on limited raw material suppliers could affect profit margins.
Opportunities: Increasing cancer incidence rates worldwide present lucrative growth opportunities. Emerging markets offer untapped potential for market expansion.
Threats: Patent expiries of blockbuster drugs enable entry of cheaper generics. Alternative treatment therapies present competition. Stringent regulations delay product approvals.
Key Takeaways:
The Global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing cancer incidence rates worldwide. North America dominated the market, owing to strong healthcare infrastructure and favorable reimbursement scenario. Europe secured the second largest share in 2023 due to rising government support for cancer care.
Regional analysis:
North America accounted for the largest share of over 30% in 2023 due to strong government support and increasing healthcare spending. Europe held the second largest share supported by favorable regulations. Asia Pacific is expected to exhibit the fastest growth during the forecast period owing to increasing patient disposable incomes, advanced pharmaceutical treatments in emerging countries like India and China.
Key players analysis:
Key players operating in the cancer chemotherapy associated nausea and vomiting therapeutics market are Johnson & Johnson Services, Inc., Teleflex Incorporated, Cooper Surgical, Inc., Genicon, Medtronic, B. Braun SE, Applied Medical Resources Corporation, LaproSurge, Purple Surgical, CONMED, Hangzhou Boer Medical Instruments Co., Ltd., Duomed, Changzhou Cheayoo Medical Devices Co., Ltd., and Tianjin Zhichao Medical Technology Co., Ltd.
For More Insights, Read: https://www.newswirestats.com/cancer-chemotherapy-associated-nausea-and-vomiting-therapeutics-market-demand-growth-and-regional-outlook-by-2030/
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments.
Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others.
The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others.
The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58According to this study, over the next five years the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market will register a 5.9% CAGR in terms of revenue, the global market size will reach US$ 96 million by 2024, from US$ 72 million in 2019.
In particular, this report presents the global market share (sales and revenue) of key companies in Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business, shared in Chapter 3.This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by product type, application, key manufacturers and key regions and countries.This study considers the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs value and volume generated from the sales of the following segments:Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.5-HT3 InhibitorsNK1 InhibitorsOtherSegmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.Highly Emetogenic ChemotherapyModerately Emetogenic ChemotherapyLow Emetogenic ChemotherapyOtherThis report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.AmericasUnited StatesCanadaMexicoBrazilAPACChinaJapanKoreaSoutheast AsiaIndiaAustraliaEuropeGermanyFranceUKItalyRussiaSpainMiddle East & AfricaEgyptSouth AfricaIsraelTurkeyGCC CountriesThe report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.
The key manufacturers covered in this report: Breakdown data in in Chapter 3.MerckEisaiMundipharmaQilu PharmaTevaNovartisHeron TherapeuticsRocheMylanTesaroResearch objectives:To study and analyze the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.To understand the structure of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by identifying its various subsegments.Focuses on the key global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs submarkets, with respect to key regions (along with their respective key countries).To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58Table of content1 Scope of the Report1.1 Market Introduction1.2 Research Objectives1.3 Years Considered1.4 Market Research Methodology1.5 Economic Indicators1.6 Currency Considered2 Executive Summary2.1 World Market Overview2.1.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption 2014–20242.1.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption CAGR by Region2.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Type2.2.1 5-HT3 Inhibitors2.2.2 NK1 Inhibitors2.2.3 Other2.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption by Type2.3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Market Share by Type (2014–2019)2.3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue and Market Share by Type (2014–2019)2.3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sale Price by Type (2014–2019)2.4 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Application2.4.1 Highly Emetogenic ChemotherapyCONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
